Yang Yu, Yang Hua, McNutt Michael A, Xiong Fuxia, Nie Xiu, Li Li, Zhou Rouli
Department of Pathology, Peking University Health Science Center, Beijing, P.R. China.
Oncol Rep. 2008 Nov;20(5):1077-83.
Lysosome-associated protein transmembrane 4beta (LAPTM4B) is a member of the mammalian 4-tetratransmembrane spanning protein superfamily, which is strongly expressed in some solid malignancies. The present study investigated the correlation of LAPTM4B expression with clinicopathological features and prognosis in ovarian carcinoma. Expression of LAPTM4B was evaluated semiquantitatively by immunohistochemistry in 85 cases of ovarian carcinoma. High LAPTM4B expression was found in 54 (63.5%) of these 85 carcinomas, and was positively correlated with FIGO stage, histological subtype and residual tumor after primary surgery, but not with age and tumor grade. Patients with high LAPTM4B expression had significantly poorer overall survival (OS) and progression-free survival (PFS) (P<0.001 and P<0.001, respectively) compared to patients with low expression of LAPTM4B. On multivariate analysis, LAPTM4B expression was found to be an independent prognostic factor for OS and PFS (P=0.01 and P=0.03, respectively). These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with unfavorable clinical outcome, suggesting that LAPTM4B may be a clinically useful prognostic indicator for ovarian carcinoma.
溶酶体相关蛋白跨膜4β（LAPTM4B）是哺乳动物四跨膜蛋白超家族的成员，在某些实体恶性肿瘤中强烈表达。本研究调查了LAPTM4B表达与卵巢癌临床病理特征及预后的相关性。采用免疫组织化学方法对85例卵巢癌组织中LAPTM4B的表达进行半定量评估。在这85例癌组织中，54例（63.5%）呈现LAPTM4B高表达，其与国际妇产科联盟（FIGO）分期、组织学亚型及初次手术后残留肿瘤呈正相关，但与年龄和肿瘤分级无关。与LAPTM4B低表达的患者相比，LAPTM4B高表达的患者总生存期（OS）和无进展生存期（PFS）明显更差（分别为P<0.001和P<0.001）。多因素分析显示，LAPTM4B表达是OS和PFS的独立预后因素（分别为P=0.01和P=0.03）。这些结果表明，LAPTM4B高表达与卵巢癌进展相关且与不良临床结局相关，提示LAPTM4B可能是卵巢癌临床有用的预后指标。
